Claes Wollheim
Switzerland
Research Article
Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes
Author(s): Pascale Fouqueray, Xavier Leverve (In Memoriam), Eric Fontaine, Mathurin Baquié, Claes Wollheim, Harold Lebovitz and Sophie BozecPascale Fouqueray, Xavier Leverve (In Memoriam), Eric Fontaine, Mathurin Baquié, Claes Wollheim, Harold Lebovitz and Sophie Bozec
Study background: The objective of this collated research paper is to highlight the anti-diabetic effects and mode of action of imeglimin, the first in a new tetrahydrotriazine-containing class of oral anti-diabetic agents: the glimins. Imeglimin acts on both insulin resistant organs (liver and muscle) and pancreatic β-cells (insulin secretion in response to glucose and protection against apoptosis).
Methods: The aim of the investigations reported here is to present data on the mode of action of imeglimin and its anti-diabetic effects, demonstrating that it represents a promising treatment for type 2 diabetes by acting on the three key pathological defects of the disease, namely excessive hepatic glucose production, impaired peripheral glucose uptake by skeletal muscle, and insufficient insulin secretion.
.. View More»
